Abstract
This study evaluates the prognostic value of vascular endothelial growth factor A (VEGF-A) and hepatocyte growth factor receptor (HGFR, c-met) expressions in a homogenous group of 98 patients with Stage II invasive ductal breast carcinoma. While a strong biological correlation was observed between VEGF-A and c-met expression, neither marker correlated with clinical parameters (tumor size, grade, lymph node status) or long-term survival (5- and 10-year DFS/OS). The findings suggest that while these pathways are linked, they do not serve as independent prognostic indicators in this specific patient population.
Introduction
Identifying reliable biomarkers for Stage II breast cancer is a critical clinical challenge. While some patients require aggressive intervention, others may be overtreated. This study focuses on two key pathways: the Hepatocyte Growth Factor (HGF)/c-met axis, involved in cell proliferation, and Vascular Endothelial Growth Factor A (VEGF-A), a primary driver of angiogenesis. Given conflicting reports in existing literature, this research aims to clarify their prognostic utility within a strictly defined patient cohort.
Methods
The researchers analyzed archival tumor samples from 98 patients diagnosed with Stage II invasive ductal breast carcinoma at the Lower Silesian Oncology Center. All patients underwent primary surgery (modified radical mastectomy).
Protein expression was assessed using Immunohistochemistry (IHC). Staining intensity and prevalence were scored on a semi-quantitative scale from 0 to 3. For example, Level 2 indicated that 33–66% of cells were stained.
Statistical analysis included Pearson and Spearman rank correlations to evaluate the relationship between markers, and Kaplan-Meier curves with log-rank tests to assess 5-year and 10-year Disease-Free Survival (DFS) and Overall Survival (OS).
Results
The study found that both markers were frequently expressed in the tumor samples, with c-met positivity at 63% and VEGF-A positivity at 69%.
Biological Correlation
A statistically significant correlation was identified between c-met and VEGF-A expression (Pearson’s $p=0.0176$; Spearman’s $p=0.0205$). This supports the hypothesis of biological "crosstalk," where HGF/c-met signaling may stimulate VEGF-A production.
Clinical and Prognostic Outcomes
Despite the biological link, neither marker showed a significant association with:
- Clinical parameters (age, tumor size, malignancy grade, or axillary lymph node status).
- Long-term survival outcomes (no significant difference in 5-year or 10-year DFS or OS between high and low expression groups).
Discussion
The strong correlation between c-met and VEGF-A confirms their cooperative role in tumor biology, likely contributing to a pro-angiogenic environment. However, the lack of prognostic significance in this study contrasts with some previous findings. The authors attribute this to the homogeneity of their patient group. By focusing exclusively on Stage II ductal carcinoma, the study may have eliminated confounding variables present in more diverse cohorts, suggesting that these markers' prognostic value might be stage-dependent or more pronounced in heterogeneous populations.
Conclusion
While c-met and VEGF-A are biologically linked in breast cancer progression, they do not appear to be effective independent prognostic tools for Stage II invasive ductal carcinoma. Future research with larger, multi-center cohorts may be necessary to determine if these markers hold value when integrated into broader molecular profiling panels.
Summary updated